Search
Patients with Crohn's disease maintained steroid-free remission for three years with Lilly's Omvoh (mirikizumab-mrkz)
February 19, 2026 - … modified non-responder imputation (mNRI), presented in the About VIVID Clinical Trial Program section below. † Crohn's … placebo in the first 12 weeks (incidence rate: 16.9 vs. 30.9 per 100 patient-years), and by nearly 70% during weeks … are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/news , or follow us on Facebook , …
Sun, 06/22/2025 - 19:30 - … Lilly ADA Investor Presentation 1.5 MB June 22, 2025 at 7:30 PM EDT … Lilly ADA Investor Presentation 1.5 MB June 22, 2025 at 7:30 PM EDT …
Wed, 10/30/2024 - 10:00 - … 1.2 MB Q3 2024 Financial Workbook 67.4 KB October 30, 2024 at 10:00 AM EDT … 1.2 MB Q3 2024 Financial Workbook 67.4 KB October 30, 2024 at 10:00 AM EDT …
Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together delivered superior efficacy in first-of-its-kind Phase 3b trial for adults with psoriasis and obesity or overweight
February 18, 2026 - … weight reduction at Week 36. Participants must have a BMI ≥30 kg/m², or ≥27 to <30 kg/m² with at least one … by visiting online at http://www.pregnancyregistry.lilly.com . You are breastfeeding or planning to breastfeed. It is … problems to lose excess body weight and keep the weight off. moderate-to-severe obstructive sleep apnea (OSA) and …
Lilly to participate in TD Cowen's 46th Annual Health Care Conference
February 16, 2026 - … of Lilly's investor website at https://investor.lilly.com/webcasts-and-presentations . A replay of the presentation … available on this same website for approximately 90 days. About Lilly Lilly is a medicine company turning science into … are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/news , or follow us on Facebook , …
USOPC Announces the Team USA Athlete Recovery Program in Partnership with Eli Lilly and Company
February 16, 2026 - … forever grateful for the support that got me to Paris ." About Lilly Lilly is a medicine company turning science into … are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/news , or follow us on Facebook , Instagram , and … are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/news , or follow us on Facebook , …
Lilly's Retevmo (selpercatinib) delivers substantial event-free survival benefit as an adjuvant therapy in early-stage RET fusion-positive lung cancer
February 16, 2026 - … as adjuvant therapy in this population. NSCLC accounts for about 85 percent of all lung cancer diagnoses in the U.S. , and around 30 percent of patients with NSCLC present with stage IB-IIIA … are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/news , or follow us on Facebook , …
Lilly to acquire Orna Therapeutics to advance cell therapies
February 9, 2026 - … Goodwin Procter LLP is acting as legal counsel to Orna. About Lilly Lilly is a medicine company turning science into … law. Refer to: Ashley Hennessey ; gentry_ashley_jo@lilly.com ; 317-416-4363 (Media) Michael Czapar; czapar_michael_c@lilly.com ; 317-617-0983 (Investors) Alex Lobo ; …
Lilly reports fourth-quarter 2025 financial results and provides 2026 guidance
February 4, 2026 - … impairment, restructuring and other special charges .07 .30 Net losses (gains) on investments in equity securities … call through a link on Lilly's website at investor.lilly.com/webcasts-and-presentations . The conference call will … into the underlying trends in the company's business. About Lilly Lilly is a medicine company turning science into …
Lilly selects Pennsylvania as home for its newest injectable medicine and device manufacturing facility
January 30, 2026 - … medicine and device manufacturing facility January 30, 2026 Corporate General The $3.5 billion Lehigh Valley … investment here is more than just building a facility—it's about building a shared future with the people and … are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/news , or follow us on Facebook , …